SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in the U.S. midterms and prospects of a sweep are driving QQQ discussion, with traders connecting the selloff to fears of tighter AI and data-center rules and a rotation out of tech. Views are split between further pressure on AI-linked stocks and a possible relief bounce, with some arguing the reaction is overdone or that gridlock could limit policy changes.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

A projected Democratic sweep in the midterms dominates discussion, with traders linking the anticipated loss of Republican control to pressure on Trump Media and many voicing bearish views on the stock. The community is largely celebrating the political setback, though some posts dispute the projected results or expect Republicans to retain control.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

The midterm election results are driving debate over perceived political risk to SpaceX, with traders fearing increased scrutiny of Musk, government contracts, and data-center projects; these consequences remain speculative. The community is split between bearish calls for further losses and buyers treating the selloff as an opportunity, with some noting a rebound.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

A heavily political debate over an expected Democratic midterm sweep dominates, with traders linking Teslas selloff to possible scrutiny of Elon Musk, reduced political support, and greater uncertainty around a potential SpaceX merger. Most commentary is bearish, while some traders argue Democrats could restore EV incentives or see the drop as a buying opportunity; the election-related claims remain speculative in the discussion.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty is driving debate over whether Democratic gains could bring tighter AI and data-center rules, pressuring Nvidia and the broader AI trade; others argue gridlock would limit policy changes and infrastructure demand remains strong. Traders also point to AMDs strong results as evidence of resilient AI-chip demand, alongside a rebound in semiconductor stocks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Midterm-election fears over potential data-center restrictions dominated discussion, with traders linking the volatility in Micron and other AI-linked stocks to uncertainty about the results. Bulls argued that AI infrastructure and memory demand remain intact, while AMDs strong results helped fuel hopes of a semiconductor rebound; others remained wary of the sharp swings and memory-cycle risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected quarterly results and upbeat outlook, driven by AI and data-center demand, are drawing attention and fueling a bullish reaction. Traders are debating whether that growth can outweigh concerns about valuation, cash flow, and possible data-center restrictions tied to election outcomes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXLs volatility is centered on election-related fears that a Democratic sweep could bring data-center restrictions and slow AI chip demand; others argue the concern is overblown and point to strong AMD and SMCI earnings as support for a semiconductor rebound.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is rebounding as traders point to Apples warning that memory costs are expected to keep rising, which they see as support for memory makers pricing amid AI and data-center demand. The bounce follows a sharp selloff, and skepticism persists over whether the memory upcycle can last and whether data-center spending will hold up.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros much-better-than-expected quarterly results and higher fiscal-year outlook, driven by AI-server demand, dominate discussion. Many traders see the results as bullish but are frustrated that the shares gave back part of their post-earnings gains; others cite thin margins, cash-flow and customer-concentration risks, lingering trust concerns, and election-related market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire LOS ANGELES, June 8, 2026 LOS ANGELES, June 8, 2026 /PRNewswire...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

GRCE Stock On Track For Worst Week In 5.5 Years —  What’s Driving The Selloff?

Equity

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.


GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. 


GRCE Stock In Spotlight Ahead Of FDA Verdict On Brain Bleed Drug This Week 

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Grows By 300.8%

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.</li><li>However, the FDA issued a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application.</li><li>Analysts from Craig-Hallum and TD Cowen slashed price targets on the stock on Friday following the FDA decision.</li></ul><p>Shares of Grace Therapeutics (GRCE) are on track for their worst week since Sept. 2020, after the U.S. Food and Drug Administration refused to approve its experimental drug for the treatment of a severe form of acute brain injury, sparking price target cuts.</p><p>Shares of the company are down 49% this week, if losses hold.</p><h2 class="st-heading-2">FDA Rejection</h2><p>Grace was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage (aSAH), or bleeding over the surface of the brain in the space between the brain and the skull as a result of a ruptured brain aneurysm.</p><p>However, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/grce-stock-plunges-after-fda-rejects-brain-injury-drug-company-says-concerns-are-fixable/cZBQevVReTT">issued </a>a letter to it on Thursday, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of its application. The agency highlighted leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization, it said.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>Craig-Hallum lowered the firm's price target on Grace Therapeutics to $4 from $11 and kept a ‘Buy’ rating on the shares following the announcement. The firm believes Grace has enough runway to address the deficiencies highlighted by the FDA and an application resubmission, though shares are unlikely to move higher until further visibility is provided, it said.</p><p>TD Cowen analyst Stacy Ku also lowered the firm's price target on Grace Therapeutics to $8 from $12 and kept a ‘Buy’ rating on the shares. The firm noted that GTx-104's rejection is related to CMC, with no requests for additional clinical data. Management will seek a meeting with the FDA, which should clarify resubmission timelines, the analyst said. The firm assumes a roughly 12-month delay, with potential for faster resolution.</p><h2 class="st-heading-2">Grace Chimes In</h2><p>“We are confident in the robust data package supporting our NDA (application) submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” CEO Prashant Kohli said on Thursday following the receipt of the FDA letter.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GRCE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>A Stocktwits user highlighted that the issues cited by the FDA are fixable and the stock will bounce back up.</p><p><stembedurl>https://www.stocktwits.com/h8ster/message/651317731</stembedurl></p><p>Another user dismissed the rejection and instead highlighted possible risks of dilution from capital raising initiatives.</p><p><stembedurl>https://www.stocktwits.com/Stockseeking/message/651266436</stembedurl></p><p><a href="https://stocktwits.com/symbol/GRCE">GRCE stock</a> is down 8% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-on-track-for-best-week-ever-on-fda-push-for-psychedelics/cZBhaQDReck">CMPS On Track For Best Week Ever On FDA Push For Psychedelics</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Current Price	$1.84
Prev Close	$1.81
Open	$1.80
Dividend Yield	0.00%
50-Day Moving Average	$2.06
Beta	1.11
Avg. Volume	122,933.78
PE Ratio	-1.55

52-Week High	$5.18
52-Week Low	$1.67
Market Capitalization	$38.08M
EPS (Annual)	-$0.472
Price to Book	0.62
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GRCE Fundamentals